Risperdal® Stroke Lawyer
Approved in the 1990s as a type of new atypical anti-psychotic drug and thought to initially have fewer unwanted side effects, Risperdal® uses upon approval only included schizophrenia treatment. Risperdal® is often prescribed to control behavioral disorders in elderly patients with dementia and Alzheimers disease, including delusions, aggression, and anxiety, but the recent Risperdal® stroke announcement shows there is an increased risk in prescribing Risperdal® to a wider range of patients.
The concern with the growing power large pharmaceutical companies have has been a concern because of the influence exercised over safety regulations in pursuit of financial gain instead of patient safety. The worlds second biggest maker of medical products, Johnson & Johnsons Risperdal® schizophrenia drug has annual global sales of $2.1 billion. While a J&J spokesperson claimed an update to the Risperdal® label is indeed being made, and we will be sending out letters to health care professionals soon, the company had already issued Risperdal® warning letters to Canadian doctors and pharmacists six months before announcing Risperdal® side effect risks in the U.S.
In October 2002, J&J sent Canadian physicians and pharmacists Risperdal® warning letters that cited 37 reports of stroke or stroke-like events such as blood clots and hemorrhages that included 16 deaths. The Canadian Risperdal® warning letter also noted that two clinical trials of elderly dementia patients in which elderly Risperdal® dementia patients had a higher proportion of strokes or related events than patients that had received placebo. Risperdal® clinical trials have shown that 4% of Risperdal® patients suffered stroke or stroke-related events, opposed to just 2% of people receiving placebos. There were four Risperdal® deaths and just one death amongst placebo recipients.
Clinical trials testing Risperdal® in Alzheimer patients heightened concerns that the occurrence of serious Risperdal® side effects is higher than previously thought. Among 764 Risperdal® patients, 29 cases of stroke and stroke-related events were seen, in addition to four deaths. A Public Citizen consumer watchdog group pharmacist and research analyst thinks that the recent Risperdal® studies should push U.S. regulators to deeper examine if younger aged schizophrenia patients are also more prone to experiencing Risperdal® stroke and other side effects of Risperdal®.
For more information on Risperdal® side effects please contact us to confer with a Risperdal® lawyer.